A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This study is open to people with and without kidney problems. People can join the study if
they are 18 years or older and have a body mass index (BMI) between 18.5 and 35 kg/m2.
Iclepertin is a medicine that is being developed to treat diseases of the brain. The purpose
of this study is to find out whether having kidney problems influences how iclepertin is
taken up in the body. All participants take iclepertin once as a tablet.
Participants are in the study for 2 to 3 weeks. During this time, they visit the study site 6
times. For one of the visits, participants stay 4 nights at the study site. The site staff
measures the amount of iclepertin in the blood. The doctors also regularly check
participants' health and take note of any unwanted effects.